Table. 1.
Clinical characteristics of the total study population (N = 44) at baseline including the comparison between adjuvant- and neoadjuvant-treated patients.
| Baseline characteristics | Total n = 44 | Adjuvant n = 26 | Neoadjuvant n = 18 | p value |
|---|---|---|---|---|
| Age – Years | ||||
| Mean (SD) | 59 (6) | 59 (6) | 58 (5) | 0.478 |
| BMI - kg/m2 | ||||
| Median (IQR) | 26 (5) | 26 (4) | 26 (7) | 0.943 |
| Weight loss past 3–6 months - in kg | ||||
| <5% | 40 (91) | 24 (92) | 16 (89) | 1.000 |
| 5–10% | 4 (9) | 2 (8) | 2 (11) | |
| Clinical tumour stage - No (%)1 | ||||
| Stage I | 17 (40) | 15 (58) | 2 (12) | 0.001 |
| Stage II | 23 (54) | 11 (42) | 12 (71) | |
| Stage III | 3 (7) | 0 (0) | 3 (18) | |
| Tumour-type - No (%) | ||||
| Invasive carcinoma of no special type (NST) | 33 (75) | 17 (65) | 16 (89) | 0.089 |
| Lobular | 8 (18) | 6 (23) | 2 (11) | |
| Mucinous | 2 (5) | 2 (8) | 0 (0) | |
| Unknown | 1 (2) | 1 (4) | 0 (0) | |
| Therapeutic antibiotic use last year - No. (%) | 12 (27) | 8 (31) | 4 (22) | 0.733 |
| Weeks between collection T0 faecal sample and last therapeutic antibiotic treatment | ||||
| Mean (SD) | 31 (13) | 29 (12) | 33 (15) | 0.713 |
| Karnofsky Performance Score - No (%)* | ||||
| 70–80 | 9 (21) | 7 (27) | 2 (11) | 0.006 |
| 90–100 | 35 (79) | 19 (73) | 16 (89) | |
| MUST-score - No (%) | ||||
| Low risk | 38 (86) | 22 (85) | 16 (89) | 0.688 |
| Medium risk | 6 (14) | 4 (15) | 2 (11) | |
| High risk | 0 (0) | 0 (0) | 0 (0) | |
| Oral contraception use past | 34 (77) | 19 (73) | 15 (83) | 0.489 |
*Percentages do not add up to 100% due to rounding.